Platelet serotonin studies in affective disorders: evidence for a serotonergic abnormality?

Herbert Y. Meltzer and Ramesh C. Arora

in 5-Hydroxytryptamine in Psychiatry

Published in print February 1991 | ISBN: 9780192620118
Published online March 2012 | e-ISBN: 9780191724725 | DOI:
Platelet serotonin studies in affective disorders: evidence for a serotonergic abnormality?

Show Summary Details


This chapter considers four types of studies of platelet serotonergic measures in affective disorders: active 5-HT uptake, [3H]imipramine binding, [3H]paroxetine binding, and 5-HT2 binding site or receptor studies. Various abnormalities of serotonergic processes have been demonstrated in patients with major depression or in post-mortem specimens from depressed patients or suicides. The most direct evidence of this type involves measurement of brain 5-hydroxytryptamine (5-HT, serotonin), its major metabolite 5-hydroxyindoleacetic acid (5-HIAA), or brain 5-HT receptor and [3H]imipramine-binding (IB) sites in suicides or deceased depressed patients. Less direct measures of serotonergic function in depression include studies of cerebrospinal fluid (CSF) 5-HIAA concentration, plasma tryptophan in relation to the concentrations of large neutral amino acids, and the hormone and behavioural responses to challenges with tryptophan, 5-hydroxytryptophan (5-HTP), various direct 5-HT agonists, such as raeta-chlorophenylpiperazine (m-CPP), buspirone, 6-chloro- 2-[l-piperazinyl]pyrazine (MK 212) or fenfluramine, a 5-HT releaser. Perhaps the most indirect means of studying a possible disturbance of serotonergic mechanisms in depression involves the blood platelet, which is the subject of this chapter.

Keywords: [3H]imipramine binding; serotonergic process; 5-hydroxyindoleacetic acid; cerebrospinal fluid; plasma tryptophan; blood platelet

Chapter.  17412 words. 

Subjects: Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.